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Abstract 
 
Objective: To determine the effectiveness of a web-based self-management programme for 
people with type 2 diabetes in improving glycaemic control and reducing diabetes-related 
distress.   
 
Methods 
Design: Individually randomised two-arm controlled trial 
 
Setting: 21 General Practices in England  
 
Participants: Adults aged 18 or over with a diagnosis of type 2 diabetes registered with 
participating general practices 
 
Intervention and comparator: Usual care plus either HeLP-Diabetes, an interactive, 
theoretically informed, web-based self-management programme or a simple, text-based 
website containing basic information only. 
 
Outcomes and data collection: Joint primary outcomes were glycated haemoglobin 
(HbA1c) and diabetes-related distress, measured by the Problem Areas in Diabetes (PAID) 
scale, collected at 3 and 12 months after randomisation, with 12 months the primary 
outcome point. Research nurses, blind to allocation collected clinical data; participants 
completed self-report questionnaires online.   
 
Analysis: The analysis compared groups as randomised (intention to treat) using a linear 
mixed effects model, adjusted for baseline data with multiple imputation of missing values.  
 
Results 
Of the 374 participants randomised between September 2013 and December 2014, 185 
were allocated to the intervention and 189 to the control.  Final (12 month) follow up data for 
HbA1c were available for 318 (85%) and for PAID 337 (90%) of participants.  Of these, 291 
(78%) and 321 (86%) responses were recorded within the pre-defined “window” of 10-14 
months. Participants in the intervention group had lower HbA1c than those in the control 
(mean difference -0.24%; 95% Confidence Interval -0.44 to -0.049; p=0.014). There was no 
significant overall difference between groups in the mean PAID score (p=0.21), but pre-
specified subgroup analysis of participants who had had diabetes for less than 7 years 
showed a beneficial impact of the intervention in this group (p = 0.004).  There were no 
reported harms.  
 
Conclusions  
Access to HeLP-Diabetes improved glycaemic control over 12 months.   
 
Registration 
Trial registration ISRCTN02123133. 
 
 
 
Word count of abstract = 299.   
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Strengths and Limitations of this study 
 
 The trial recruited to target and achieved reasonable follow-up; hence the results for the 
population of participants are robust (internal validity); 
 The two co-primary outcomes reflected the goals of the intervention, namely improving 
diabetes control and reducing diabetes-related distress; 
 However, despite wide inclusion criteria and a deliberately pragmatic design, trial 
participants were well-controlled at baseline, and therefore the extent to which the trial 
results generalise to the wider population of people with type 2 diabetes is open to 
discussion (external validity). 
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Introduction.  
 
There is a global epidemic of type 2 diabetes mellitus (T2DM). An estimated 422 million 
adults, or 10% of the global population, were living with diabetes in 2014 of whom around 
90% had type 2 diabetes.1  Poorly controlled diabetes is associated with premature mortality, 
and a high risk of complications, including cardiovascular disease, nephropathy and 
retinopathy.  The risk of complications can be reduced by good control of glycaemia  and 
cardiovascular risk factors. 2 3  Interventions which improve self-management skills for 
patients with diabetes can improve health outcomes and reduce health care costs4 and 
international guidelines support training patients in self-management. 3 5 However, it is not 
clear how best to support patients in developing such skills, and uptake of diabetes self-
management education remains low. In England, despite over 90% of eligible patients being 
referred, 6 only 5.3% attended self-management training in 2014 – 15. 7  
 
Poor uptake may be related to the dominant model of structured education, which is group-
based sessions, lasting a half or whole day, or spread over regular sessions over several 
weeks. 8  Many patients, such as those who work, those with caring commitments, or those 
who are uncomfortable in groups, may find it difficult to attend.9 10   
 
Web-based support for self-management could address some of these barriers, particularly 
in high income countries, where levels of web-access are high.  In the UK over 80% of 
households had Internet access in 2015, and internet access amongst older people 
continues to grow steadily. 11 12  Potential advantages include convenience, anonymity, 
regular updates, and the potential to use video and graphics to present complex information 
in a format accessible to those with low literacy.13  Although systematic reviews have 
confirmed that computer-based interventions can improve health outcomes in diabetes 14, 
not all such interventions have a beneficial impact, with meta-analyses showing substantial 
heterogeneity related to widely differing interventions, including in the use of theory to 
develop the intervention, 15 outcomes, 14 16 and the duration of follow-up, with most trials 
having relatively short follow-up (less than 12 months). 14  This is the first UK-based trial of a 
comprehensive, web-based self-management support programme for people with type 2 
diabetes.  
 
This trial assessed the effects of a web-based self-management programme, called Healthy 
Living for People with Diabetes (HeLP-Diabetes), on glycated haemoglobin (HbA1c) and 
diabetes-related distress over 12 months.  
 
 
Methods. 
 
Trial Design and participants: multi-centre, two-arm individually randomised controlled trial in 
21 General Practices in England with a mix of urban, suburban and rural practices. Practices 
were required to have two nurses – one to facilitate access to the intervention, and one to 
collect data.  
 
Recruitment: standard opt-in recruitment procedures were followed.  Each practice had a 
register of patients with T2DM.  The electronic medical record of every patient on this 
register was reviewed to screen out ineligible patients, and the remainder were sent a letter 
from their GP, inviting them to participate in the study.  Eligible participants were adults, 
aged 18 or over, with T2DM, registered with participating general practices.  Patients were 
excluded if they were unable to provide informed consent; unable to use a computer due to 
severe mental or physical impairment; had insufficient spoken or written English to use the 
intervention (operationalised as unable to consult without an interpreter); were terminally ill 
with less than 12 months life expectancy; or were currently participating in a trial of an 
alternative self-management programme.  Participants were not required to have home 
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Internet access or prior experience of using the Internet to participate.  Participants with 
previous or current experience of self-management education were eligible to participate.  
Recruitment took place between September 2013 and December 2014.  The trial protocol 
was submitted for publication in June 2014.17 There were no changes to the methods after 
the protocol was agreed and the start of the trial. Ethical approval was obtained from 
Camden and Islington National Research Ethics Service (NRES) committee, reference 
12/LO/1571.   
 
Patient involvement 
Patients were involved in all stages of the study, including contributing to the original 
application for funding as co-investigators; substantive and ongoing contribution to 
intervention development; contributing to the trial design, including the decision to have two 
co-primary outcomes; active membership of the Trial Steering Committee and Trial 
Management Group; and contributing to the writing of this paper.  This last role is recognised 
through co-authorship (MK). 
 
Randomisation and blinding 
Randomisation marked the point of study entry. It was performed centrally (independently of 
the trial team), after written informed consent was obtained and all baseline data were 
completed, using a web-based randomisation system, at the level of the individual 
participant. Randomisation was conducted in a 1:1 ratio using random permuted blocks of 
sizes 2, 4 and 6, stratified by recruitment centre.  Participants were informed the trial 
compared two forms of web-based support, and were blinded as to which was the 
intervention and which the comparator.  Nurses who offered facilitation for the intervention 
could not be blinded, but were asked not to discuss details of allocation with the nurses who 
gathered follow-up data.  The research team obtaining and analysing data from participants 
were blind to allocation.  
 
Intervention 
The intervention consisted of facilitated access to HeLP-Diabetes. Facilitation consisted of 
an introductory training session with the practice nurse. In this appointment patients were 
were shown how to log on, set a user name and password, and introduced to the content of 
the website. HeLP-Diabetes was a theoretically informed web-based programme whose 
overall goals were to improve health outcomes and reduce diabetes-related distress.18 
Overall content was guided by the Corbin and Strauss model of managing a long term 
condition which posits that patients must undertake medical, emotional and role 
management.19 It was developed using participatory design principles, with substantial input 
from users, defined as patients with T2DM and health professionals caring for such patients. 
All content was evidence-based, drawing on evidence on management of diabetes, 
promoting behaviour change and emotional wellbeing, and maximising usability and 
engagement. Content was designed to be accessible to people with a wide range of literacy 
and health literacy skills, with all essential content provided in both video and text.  There 
were information sections on diabetes, how diabetes is treated, possible complications of 
diabetes, possible impacts of diabetes on relationships at home and at work, dealing with 
unusual situations like parties, holidays, travelling or shift work, and what lifestyle 
modifications will improve health. There were sections addressing skills and behaviour 
change, including behaviour change modules on eating healthily, losing weight, being more 
physically active, smoking cessation, moderating alcohol consumption, managing medicines, 
glycaemic control and blood pressure control. Users could set the programme to send 
themselves reminder text messages or emails, and could specify the content and frequency 
of such reminders.  The third strand of components focused on emotional well-being with 
self-help tools based on cognitive behavioural therapy and mindfulness.  There were multiple 
personal stories (used with license from health talk online), and a moderated forum. 
Participants were free to use the programme as much or as little as they chose. Engagement 
with the programme was promoted through regular newsletters, emails and SMS containing 
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updates on latest diabetes-related research or practice, seasonally-relevant advice (e.g. 
fasting during Ramadan, benefits of ‘flu vaccinations), and links to specific relevant parts of 
the programme. Two or three prompts were sent each month, although users could opt out 
of receiving them. Further details are provided in Appendix 1.  
 
Comparator 
From an NHS perspective, the important research question was whether the proposed 
intervention could improve health outcomes when compared to current practice.  However, 
to improve acceptability to participants and to maintain blinding, all participants had access 
to a website.  Participants in the control arm were given access to a simple information 
website, based on the information available on the website of the main UK diabetes charity 
(Diabetes UK) or National Health Service patient information website (NHS Choices). They 
received the same initial facilitation meeting as participants in the intervention group, in 
which they were shown how to log on, set a user name and password, and how to use the 
website.  
  
 
Outcomes and outcome measures 
 
Primary outcomes 
The outcomes reflected the dual goals of improving health outcomes and reducing diabetes-
related distress. The two joint primary outcomes were glycated haemoglobin (HbA1c) and 
diabetes-related distress, measured by the Problem Areas in Diabetes (PAID) scale, both at 
12 months post-randomisation. PAID has 20 items focusing on areas that cause difficulty for 
people living with diabetes, including social situations, food, friends and family, diabetes 
treatment, relationships with health care professionals and social support.20 PAID scores 
range from 0 – 100, with higher scores indicating more distress. A score of 40 or more 
indicates significant distress, and around 40% of patients with diabetes experience 
significant distress.21  
 
Secondary outcomes 
Clinical secondary outcomes included systolic and diastolic blood pressure; body mass 
index; total cholesterol and HDL (not fasting); and completion of the “9 essential processes” 
for effective management of diabetes, mandated by NHS England (= weight, BP, smoking 
status, measurement of serum creatinine, cholesterol and HbA1c, urinary albumin and 
assessment of eyes and feet) within the previous 12 months.3 Patient-reported outcomes 
included depression and anxiety, measured using the Hospital Anxiety and Depression 
Scale (HADS);22 diabetes-related self-efficacy measured using the Diabetes Management 
Self-Efficacy Scale (DMSES);23 and satisfaction with treatment, measured using the 
Diabetes Satisfaction with Treatment Questionnaire status and change version (DTSQs & 
DTSQc).24   
 
 
Data collection 
Data were collected at baseline, 3 and 12 months, with 12 months the primary endpoint.  
Patient-reported data were collected using online questionnaires emailed to participants.  
Clinical outcomes were collected by nurses in participating practices. Participants were 
asked to complete their online questionnaires before visiting the nurse for clinical 
measurements and blood tests. Blood samples were analysed at the local NHS laboratory 
used by participating practices for routine clinical analyses. Data on completion of the “9 
essential processes” were collected from the GP record for the 12 months prior to 
randomisation and the 12 months after randomisation at the 12 month follow-up point to 
avoid triggering behaviour change amongst the study nurses.  Use of the intervention was 
recorded automatically using bespoke software that recorded the date, and time of each 
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page visited. A new log-in to the intervention was defined as any page that was accessed 30 
minutes or more after the last accessed page. 
 
Sample size Calculation 
Our original sample size calculation was that randomising 350 participants with 85% follow-
up would provide 90% power at the 5% level of significance to detect a 0.25% difference in 
HbA1c and a 4.0 point difference in PAID score at 12 months post-randomisation between 
the randomised groups.25 26  Since HbA1c and PAID were joint primary outcomes measuring 
different aspects of T2DM, both were tested at a 5% significance level.   
 
 
Analysis 
The analysis followed a pre-specified analysis plan, based on comparing the groups as 
randomised (intention-to-treat). The analysis plan was approved by the Trial Steering 
Committee before unblinding and uploaded to the trial website, 
https://www.ucl.ac.uk/pcph/research-groups-
themes/ehealth/projects/projects/helpdiabetesrct.  Only HbA1c and PAID measured within a 
10-14 month window period following randomisation was used in the primary analysis with 
missing 12-month outcomes multiply imputed using baseline and other outcome data (e.g. 
3m data and final follow-up data collected outside the 10-14 month window). Further 
information on the imputation method is given in Appendix 2.   
 
A linear mixed effects model with random centre effects was used to analyse each of the 
primary outcomes separately, adjusting for the baseline level of the outcome, age, gender, 
previous participation in other self-management programmes, pre-existing cardiovascular 
disease and time since diagnosis of diabetes. Secondary outcome measures were analysed 
similarly using generalised linear mixed models, with a  normal residual error structure for 
continuous outcomes and a logit link for the binary outcome `Completion of 9 essential 
processes’.  Pre-specified sub-group analysis for the co-primary outcomes was undertaken 
by baseline glycaemic control (HbA1c outcome only), baseline PAID (PAID outcome only), 
and duration of diabetes, treating all potential effect modifiers as continuous. The interaction 
between randomised group and each effect modifier was included in the model separately 
and assessed using a Wald test.  
 
Use of the intervention was investigated as a mediator for efficacy, using instrumental 
variable methods, with randomisation as the instrument (Supplementary Figure 1).27 28  
 
Potential contamination was monitored by recording participants with similar family names 
and identifying those with the same addresses. Where this occurred, it was dealt with in the 
analysis by reporting the extent and undertaking a sensitivity analysis excluding these 
individuals.  
 
 
A number of other sensitivity analyses were performed to assess the robustness of the primary 
analyses: 1) performing two complete case analyses disregarding outcomes measured outside 
10-14 months and 11-13 months post-randomisation; 2) repeating the analysis using multiple 
imputation of baseline covariates only; 3) fitting linear models excluding centre random-effects; 
and 4) fitting an unadjusted model using only outcome measured in 10-14 months post-
randomisation. 
 
The TSC took on the role of the data monitoring committee. Trial registration 
ISRCTN02123133. 
 
 
Results 
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Recruitment took place between September 2013 and December 2014. An initial 421 
patients consented to participate, but of these 47 did not fully complete their baseline 
questionnaires and were therefore not randomised and did not enter the study.  A total of 
374 participants were randomised, of whom 86% (n = 321) provided data on PAID, and 78% 
(n = 291) had HbA1c measured within 10 to 14 months of randomisation. Additional final 
outcome data, obtained outside the 10 – 14 month pre-defined window, were available for a 
further 27 participants for HbA1c and 16 participants for PAID (Figure 1).  Data obtained 
outside the 10 – 14 month window were not used directly in the primary analysis, but were 
entered into the imputation model (Supplementary Table 1).  
 
Baseline characteristics 
Baseline demographic and clinical characteristics are shown in Table 1.  The mean age was 
nearly 65 years, over two-thirds (n = 258, 69%) were male, and most were White British (n = 
300, 80%).  Nearly all (n=370, 99%) had a computer with access to the internet at home and 
just over half (n = 210, 56%) rated themselves as experienced computer users.  Around one-
third (n = 134; 36%) had been diagnosed for less than 5 years, with a further third (n = 115, 
31%) having been diagnosed between 5 and 9 years ago.  Overall, this was a population 
with well-controlled diabetes at baseline (mean HbA1c was 7.3% (56 mmol / mol)) and low 
levels of distress (mean PAID = 19).  
 
Primary outcomes 
At twelve months the primary analysis showed a significant difference in change in HbA1c 
between the randomised groups with participants in the HeLP-Diabetes group having a 
lower HbA1c than those in the control group (mean difference = -0.24%; 95% confidence 
intervals -0.44 to -0.049, p=0.014) (Table 2, Figure 2). There was no difference in change in 
PAID scores between the groups at 12-months (mean difference -1.5; 95% CI -3.9, 0.9, 
p=0.209), though both groups showed a decrease in PAID over the follow-up of the trial 
(Table 2, Figure 3). 
 
Secondary outcomes 
There was no difference in secondary outcomes at 12 months, with the possible exception of 
systolic blood pressure, which decreased more in the intervention group than in the control group 
(p=0.010) (Table 2); though the result was not statistically significant after correction for multiple 
testing of secondary outcomes. There were no significant differences between groups on any 
of the outcome measures amongst individuals who completed three month outcomes 
(Supplementary Table 2). No adverse effects or events were recorded during follow-up.  
 
Usage data 
The mean number of log-ins was significantly higher in the intervention group than the 
control group (18.7 vs. 4.8, p= 0.0001), as was the mean number of pages visited per log-in 
(10.5 vs. 7.7, p <0.0001) and the mean number of days in which the website was accessed 
(10.1 vs. 3.3, p<0.0001) (Table 3). The causal analyses estimated that for a “high-usage” 
population (those with usage ≥ the median of 4 days) the HeLP-Diabetes intervention could 
on average reduce HbA1c by -0.44% (95% CI -0.81 to -0.06) and PAID by -2.8 (95% CI -7.2 
to 1.7) over 12 months (Supplementary Figures 2 and 3). The mean usage in the “high-
usage” group was 18 days. It should be noted that the usage data presented do not include 
the initial facilitation visit. There was a technical error in the software which led to usage data 
not being collected before 1 January 2014.  At this point 16 participants had been 
randomised (7 to intervention, 9 to control).  For these 16 participants, the usage data is not 
based on a full year, but for all other participants, data are summarised for the 12 months 
post-randomisation.  
 
Sensitivity analyses 
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The findings from the sensitivity analyses, including a complete-case analysis, were similar 
to the main analysis (Supplementary Table 3). Participants who were missing 12-month 
HbA1c had significantly higher mean baseline HbA1c measures (7.9% vs. 7.1%, p<0.001) 
leading to higher imputed HbA1c at 12-months in the non-completers and a greater mean 
difference between the randomised groups than from complete case analyses 
(Supplementary Figure 4, Supplementary Table 3). 
 
Subgroup analyses 
Pre-specified subgroup analyses showed that there was no evidence of baseline measures 
of HbA1c or PAID being effect modifiers for the mean difference between the groups. There 
was strong statistical evidence (interaction p=0.004) to suggest that the duration of diabetes 
acted as an effect modifier, with those who had been diagnosed more recently (<7 years) 
showing more of a reduction in PAID than those who had been diagnosed for longer periods 
of time. Duration of diabetes had no effect on change in HbA1c (Supplementary Table 4).  
 
Harms 
There were no reported harms in either group.  
 
 
Discussion 
In this first UK-based trial of a web-based self-management programme for people with 
T2DM, participants randomised to HeLP-Diabetes demonstrated improved glycaemic control 
at 12 months compared to those randomised to a simple information website.  This 
improvement appears robust across all pre-specified sensitivity analyses, and was not 
dependent on duration of diabetes, baseline glycaemic levels or level of diabetes-related 
distress. Each 1% reduction in HbA1c is associated with a risk reduction of 21% for deaths 
related to diabetes and a 37% risk reduction for microvascular complications.26 A reduction 
in HbA1c of 0.24% across a population level could translate into considerable population 
benefit, particularly as this web-based intervention could be delivered at low-cost and at 
scale across the UK.  Moreover, in contrast to group-based education, where the effects 
appear to wane with time,29 the effects of HeLP-Diabetes were greater at 12 months than at 
3 months. There was no overall impact on diabetes-related distress, but some evidence that 
HeLP-diabetes appeared to reduce distress in recently diagnosed individuals. However, it is 
worth noting that baseline PAID scores were exceptionally low in this trial population. In a 
small pilot study, participants offered supported access to HeLP-Diabetes reduced their 
PAID scores by 6 points (p=0.04) over 6 weeks.30 
 
The trial has many strengths. It was a pragmatic trial, open to nearly all patients with T2DM 
in participating practices.  Concealment of allocation was complete, as randomisation 
occurred after baseline data collection. Baseline prognostic factors were well balanced 
between groups.  Every effort was made to achieve blinding, including requiring practices to 
have two nurses, so that data collection was undertaken by a nurse blind to participant 
allocation.  Data for the co-primary outcomes at the primary outcome point were available for 
78% and 86% of participants for HbA1c and PAID respectively.  All analyses were on an 
intention-to-treat basis, supplemented by a CACE analysis.   Although response rates for the 
co-primary outcomes were good, some potential for bias existed.  Our primary analysis used 
multiple imputation methods because evidence shows that the assumptions underpinning 
this method are more defensible than those assumed using other approaches to missing 
data.31 We also undertook sensitivity analyses including complete cases, non-contaminated 
cases, and a linear model excluding centre; all yielded similar results.   
 
The two co-primary outcomes reflected the twin aims of the intervention: to improve diabetes 
control and to reduce diabetes-related distress.  Around 40% of patients with diabetes have 
significant levels of distress, which severely impacts on quality of life,32 and diabetes-related 
distress is an important outcome for patients.33  Our patient and public involvement (PPI) 
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panel were clear that this should be a primary outcome, and a recent meta-ethnography 
emphasised the importance of empowerment and quality of life in promoting long term 
engagement with self-management.34  In contrast, many health care professionals are more 
interested in glycaemic control.  In line with previous trials in this area,35 we decided to adopt 
both as co-primary outcomes and to test both at a 5% level of significance.36  
 
There are some limitations. Despite maximising the inclusivity of the trial by minimising the 
exclusion criteria, participants were not representative of the overall population of patients 
with type 2 diabetes in England. Compared to the overall population, participants had better 
control of their diabetes and cardiovascular risk factors, 6 7 and were much less distressed. 21 
This finding mirrors that of a recent systematic review of demographic factors associated 
with web portal usage amongst people with diabetes which found that those with well 
controlled diabetes were more likely to use such portals than those with poor control. 37 
However, fewer of our participants self-rated their computer skills as excellent (57% of our 
sample compared to a national average of 73%).12 This good control at baseline has two 
implications – first, that there was little room for improvement in this population, and 
secondly, that this population may have been unusually motivated to self-manage their 
diabetes.  Although every effort was made to maintain blinding, it is possible that some 
participants may have discussed their use of the intervention with research nurses, making it 
possible to infer which arm they had been allocated to. This could have affected research 
nurses’ measurements of secondary clinical outcomes, such as blood pressure or weight, 
but could not have affected assessment of glycated haemoglobin as this was measured by 
laboratory staff who were blinded. There appeared to be high potential for contamination 
between two participants who shared the same surname and address, and a further two 
participants did not receive their allocated intervention due to an error at practice level; 
excluding these four made no difference to the results. A further limitation of the trial is that it 
provides little insight into the mechanism of action of HeLP-Diabetes.  This was the result of 
a deliberate decision to focus on clinically important outcomes and minimise both the 
response burden and the potential impact of measurement on participants.  
 
This is the first UK-based trial of a web-based self-management programme for people with 
type 2 diabetes, and internationally, the first trial of such a comprehensive intervention that 
aims to address the three main tasks of self-management: emotional, medical and role 
management.19 In the Cochrane review of computer-based self-management interventions 
for people with T2DM, only 4 of the included studies had follow-up of 12 months or more.14  
Of these, three interventions were clinic-based, with participants completing self-assessment 
tools on a touch screen and receiving tailored advice during their baseline visit to their 
diabetes clinician 38-40 and one was a mobile phone-based intervention which provided 
tailored messages in response to participant’s results of blood glucose self-monitoring data. 
41  A more recent systematic review of internet delivered diabetes self-management 
identified 2 trials with 12 or more months follow-up. 42 One trial was on a structured 
intervention based on a peer-led, group-based, diabetes self-management course 43. There 
were six sessions, with each session available for one week. Each session required 
participants to make a specific action plan to address a problem they were experiencing.   
Peer facilitators encouraged use of the programme.  Follow up was planned at 6 and 12 
months; however HbA1c data were only available at 6 months. The other trial compared two 
versions of a web-based intervention (with and without additional social support) to 
enhanced usual care. The web-based intervention was designed using social-cognitive 
theory and a social-ecological model, with a focus on three main behaviours: dietary intake, 
physical activity and medication adherence. Users of either web-based intervention received 
motivational phone calls to encourage adherence and development of action plans. Those 
randomised to the enhanced intervention (with additional social support) received two 
additional phone calls and an invitation to attend a group session. There was no difference 
between groups in HbA1c or other biological outcomes at 12 months. 44 Thus the results of 
this trial add significantly to the available literature.  
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On the basis of these results, HeLP-Diabetes may be considered as an addition to the 
current menu of self-management support for people with type 2 diabetes, and may help 
increase overall access and uptake.  Most commissioned services currently focus on newly 
diagnosed patients, leaving clear unmet need for people who have had their diabetes for 
longer, but are looking for ways to improve their health.  Many patients are not ready to 
engage in self-management early in their illness journey,9 but become motivated to do so 
later, often as a result of a change in medication or development of a complication.45  The 
intervention is low cost, and as most costs are fixed, irrespective of number of users, is likely 
to be cost-effective, particularly if widely used.  A cost-effectiveness analysis of HeLP-
Diabetes will be reported separately.   
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Table 1: Descriptive statistics of baseline variables by randomised group.  
Mean (SD) unless otherwise specified.  
 
 HeLP-Diabetes 
N=185 
Control  
N=189 
N missing 
Age at randomisation (yrs) 64.9 (9.5) 64.7 (9.1) 0 
Male sex, n (%) 127 (69%) 131 (69%) 0 
Ethnicity, n(%): 
White English, Welsh, Scottish, Northern Irish, British 
 
151 (82%) 
 
149 (79%) 
1 
Indian 12 (6%) 8 (4%)  
Other 21 (11%) 31 (16%)  
Experience with computers, n(%) 
None 
 
5 (3%) 
 
4 (2%) 
0 
Basic 75 (41%) 80 (42%)  
Experienced 105 (57%) 105 (56%)  
Smoking status, n(%): 
Current smoker 
 
14 (8%) 
 
14 (7%) 
0 
Former smoker 94 (51%) 86 (46%)  
Never smoker 77 (42%) 89 (47%)  
Time since diagnosis (years), n(%): 
0-4 years 
 
70 (38%) 
 
64 (34%) 
4 
5-9 years 55 (30%) 60 (32%)  
10-14 years 40 (22%) 40 (21%)  
15+ years 18 (10%) 23 (12%)  
Attending any other self-management class, n(%) 4 (2%) 4 (2%) 0 
    
Clinical Measures     
Systolic blood pressure (mmHg) 135 (17) 135 (17) 0 
Diastolic blood pressure (mmHg) 78 (11) 77 (10) 0 
Total cholesterol (mmol/l) 4.11 (1.03) 4.18 (0.98) 2 
HDL-C (mmol/l) 1.24 (0.31) 1.25 (0.36) 12 
Total cholesterol /HDL-C ratio 3.43 (1.09) 3.52 (1.03) 13 
HbA1c (%) 7.26 (1.25) 7.35 (1.37) 5 
HbA1c (mmol/mol) 56 (14) 57 (15) 5 
Body mass index (Kg/m2) 30.1 (5.3) 29.6 (5.2) 2 
Questionnaires / scores    
PAID (0-100) 18.1 (17.1) 19.9 (19.9) 0 
HADS (0-42) 9.28 (6.47) 9.12 (7.52) 0 
Anxiety scale (0-21) 4.92 (3.70) 5.21 (4.20) 0 
Depression scale (0-21) 4.36 (3.48) 3.91 (3.73) 0 
DMSES (0-150) 98.6 (33.9) 103.7 (32.4) 0 
DTSQ (0-48) 32.1 (7.3) 32.0 (7.2) 0 
    
Completion of 9 essential processes in previous 12 months, n(%) 97 (64%) 96 (62%) 69 
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Table 2: 12 month outcomes, adjusted for relevant baseline outcome, age, sex, 
current (baseline) participation in other self-management programmes, pre-existing 
cardiovascular disease and duration of diabetes.  
Results from multiply imputed data shown. Data are mean (SE) or mean difference (95% CI) 
unless otherwise specified. 
 
 HeLP-Diabetes Control HeLP-Diabetes vs Control 
 Baseline Change from 
baseline to 
12 months 
Baseline  Change 
from 
baseline to 
12 months 
Mean difference 
(95% CI) 
p-value 
Primary 
outcomes 
      
HbA1c, (%) 7.3 (0.1) -0.08 (0.07) 7.3 (0.1) 0.16 (0.07)  
-0.24 (-0.44, -0.05) 
 
0.014 
HbA1c, 
mmol/mol 
56.3 
(1.1) 
-0.8 (0.8) 56.8 
(1.1) 
1.8 (0.8) -2.6 (-4.8, -0.5) 0.014 
PAID 18.2 
(1.3) 
-4.1 (0.9) 19.8 
(1.3) 
-2.5 (0.9) -1.5 (-3.9, 0.9) 0.209 
Secondary 
outcomes 
      
Systolic 
blood 
pressure, 
mmHg 
134.7 
(1.5) 
-4.2 (1.4) 134.9 
(1.5) 
-0.5 (1.4)  
-3.8 (-6.6, -0.9) 
 
0.010 
Diastolic 
blood 
pressure, 
mmHg 
77.8 
(1.0) 
-2.5 (0.9) 77.1 
(1.0) 
-1.9 (0.8) -0.6 (-2.4, 1.2)  
0.519 
Body mass 
index, Kg/m2 
30.1 
(0.5) 
0.12 (0.2) 30.0 
(0.5) 
-0.04 (0.2) 0.16 (-0.30, 0.62)  0.498 
Total 
cholesterol, 
mmol/L 
4.1 (0.1) -0.08 (0.06) 4.2 (0.1) -0.15 
(0.06) 
0.07 (-0.09, 0.2)  
0.370 
HDL 
cholesterol, 
mmol/L 
1.25 
(0.03) 
-0.003 
(0.018) 
1.26 
(0.03) 
0.004 
(0.018) 
-0.007 (-0.054, 0.039)  
0.754 
Completion 
of 9 essential 
processes* 
65% 
(3.7) 
-5.1% 61% 
(3.8) 
3.4%  
0.78 (0.45, 1.35) 
 
0.379 
HADS 9.3 (0.5) -1.05 (0.44) 9.1 (0.5) -0.60 
(0.48) 
-0.45 (-1.68, 0.78)  
0.474 
DMSES** 98.8 
(2.4) 
2.93 (2.90) 103.6 
(2.3) 
1.38 (2.79) 1.55 (-5.74, 8.84)  
0.674 
DTSQ 32.2 
(0.6) 
0.94 (0.57) 32.2 
(0.6) 
0.45 (0.61) 0.49 (-1.18, 2.15)  
0.564 
 
* Percentage (SE) and odds ratio (95% CI) 
** linear regression results shown due to lack of convergence for mixed model 
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Table 3. Extent of website usage over 12-month follow-up. 
 
 HeLP-Diabetes Control  p-value* N missing 
Number of log-ins per person 18.7 (84.0) 4.8 (8.0) 0.0001 0 
Number pages visited per log-in 10.5 (6.7) 7.7 (5.0) <0.0001 105** 
Time spent in each log-in (minutes)*** 12.3 (9.8) 8.2 (8.4) <0.0001 105** 
Number of days in which website was accessed over follow-up 10.1 (22.9) 3.3 (5.1) <0.0001 0 
Mean (SD) unless otherwise specified.  
* Wilcoxon rank-sum test.  
** 105 individuals did not log in after their facilitation visit (42 intervention, 63 control). 
*** Measured as time from first page accessed to last page accessed within a log-in session. 
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Figure Legends 
 
Figure 1: CONSORT diagram showing patient flow through the HeLP-Diabetes Randomised 
Controlled Trial.  
 
Figure 2: Mean HbA1c (95% confidence interval) over follow up by randomised group using multiple 
imputation 
 
Figure 3: Mean PAID score (95% confidence interval) over follow up by randomised group using 
multiple imputation. 
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